Glioma of the paediatric visual pathway means a brain tumour that grows along the child’s “seeing wires.” These wires include the optic nerves (behind each eye), the optic chiasm (where the nerves cross), the optic tracts and radiations (pathways going back into the brain), and sometimes the nearby part of the brain called the hypothalamus. Most of these tumours are low-grade (slow-growing) astrocytomas, especially pilocytic astrocytomas. They make up about 3–5% of brain tumours in children and usually appear before 10 years of age. MDPI+2Nature+2
Glioma of the paediatric visual pathway (also called optic pathway glioma or optic chiasm/hypothalamic low-grade glioma) is a slow-growing brain tumour that starts in the nerves that carry images from the eyes to the brain (optic nerves, optic chiasm, optic tracts). It often happens in young children, especially those with neurofibromatosis type 1 (NF1). Most of these tumours are low-grade (WHO grade I–II), meaning they grow slowly, but they can still damage vision, hormones, growth, and behaviour because they sit in a very sensitive place in the brain.MDPI+1
These tumours press on the visual pathway and can slowly damage the child’s vision. Sometimes they also press on parts of the brain that control hormones, sleep, appetite, and growth. That is why some children have both vision problems and hormone or growth problems together. Boston Children’s Hospital+1
Other names
Doctors use several names for glioma of the paediatric visual pathway. The most common names are “optic pathway glioma” and “optic nerve glioma.” Some children’s hospitals may also call it “optic glioma,” “optic pathway and hypothalamic glioma,” or “visual pathway glioma.” All these terms describe tumours that arise along the vision pathways in the brain and behind the eyes in children. Boston Children’s Hospital+2ScienceDirect+2
Types of paediatric visual pathway glioma
There are different ways to group these tumours. One simple way is by where they sit along the visual pathway. Netsolhost+1
Optic nerve glioma – The tumour grows mainly in one optic nerve behind one eye. The nerve looks thicker and sometimes twisted on MRI scans, and the child may lose vision in that eye first. Boston Children’s Hospital+1
Chiasmatic glioma – The tumour is centred at the optic chiasm, where the two optic nerves cross. Because this area carries signals from both eyes, children can have vision loss in both eyes and may also have hormone problems due to pressure on the nearby hypothalamus. Netsolhost+1
Post-chiasmatic (optic tract and radiation) glioma – The tumour grows further back in the optic tracts or radiations deeper in the brain. These tumours can cause complex visual field loss (missing parts of the visual field) and sometimes more serious neurological problems. Dove Medical Press+1
Optic pathway–hypothalamic glioma – In some children the tumour involves both the optic pathway and the hypothalamus. These children may have special features such as very poor weight gain (diencephalic syndrome) or, in other cases, early puberty and hormone imbalance. ScienceDirect+1
Another way to group these tumours is by cause and cell type. Most are low-grade pilocytic astrocytomas, and they can be either NF1-associated (linked to the genetic condition neurofibromatosis type 1) or sporadic (happening without NF1). MDPI+2MDPI+2
Causes and risk factors
For many children, there is no single clear “cause.” Instead, doctors talk about risk factors. These are things that make the tumour more likely, but they do not guarantee it will happen. ScienceDirect+1
Neurofibromatosis type 1 (NF1) – NF1 is the strongest known risk factor. About 15–20% of children with NF1 will develop an optic pathway glioma at some point in life. The NF1 gene mistake (mutation) makes cells more likely to grow into tumours, including along the optic pathway. MDPI+2Nationwide Children’s Hospital+2
NF1 gene mutation pattern – Specific changes in the NF1 gene seem to raise the chance of optic pathway glioma even more, such as certain “hotspot” mutations. This means not all NF1 mutations carry the same level of risk. MDPI+1
Sporadic genetic changes in astrocytes – In children without NF1, random mutations in glial cells (astrocytes) can cause them to divide too much and form a glioma. These changes often occur by chance during brain development. MDPI+1
Age in early childhood – Most optic pathway gliomas are found in children younger than 10, with a peak around 4–5 years. This suggests that brain and eye development stages may play a role in when the tumour appears. Nature+2Ovid+2
Family history of NF1 or brain tumours – A family history of NF1 means the child may inherit the NF1 gene change, which then increases the risk of optic pathway glioma. Very rarely, other family tumour syndromes can also increase risk. Frontiers+1
Other tumour predisposition syndromes – Conditions like Li–Fraumeni syndrome or other rare genetic tumour syndromes can slightly increase the chance of CNS tumours, including gliomas, although optic pathway glioma itself is still uncommon. ScienceDirect+1
High birth weight in children with NF1 – Studies show that children with NF1 who have a higher birth weight seem to have a higher chance of brain tumours, including optic pathway gliomas. Dove Medical Press+1
Ethnic background in NF1 – In NF1-associated optic pathway glioma, children of Caucasian background appear more likely to be diagnosed with OPG than children of Black or Asian background, although the exact reason is not clear. Dove Medical Press+1
Female sex (in NF1) – Some studies suggest girls with NF1 may have a slightly higher risk of developing optic pathway gliomas than boys, though this difference is modest and not seen in every study. European Review+1
Allergic conditions and immune balance – Interestingly, eczema or asthma in children with NF1 may be linked with a lower risk of OPG, showing that the immune system environment can influence tumour risk. Dove Medical Press+1
Abnormal signalling pathways in glial cells – Pathways like RAS–MAPK are over-active in NF1 and in many low-grade gliomas. This abnormal signalling makes glial cells grow when they should stop, helping a tumour to form. MDPI+1
Hormone and growth factor signals near the hypothalamus – Tumours near the hypothalamus receive many growth factor and hormone signals. This “rich” environment may support tumour growth and help small lesions become larger. ScienceDirect+1
Previous head radiation – In general, radiation to the head in childhood can increase the risk of later brain tumours, including gliomas, though this is rarely the direct cause of optic pathway glioma specifically. ScienceDirect+1
Other brain developmental problems – Children with certain brain malformations or other CNS issues can, in rare cases, have a higher chance of tumour growth because brain tissue formed in an unusual way. ScienceDirect+1
Location of the tumour along the pathway – Tumours that arise behind the chiasm (post-chiasmatic) often behave more aggressively. While location does not “cause” the tumour, it is a biological factor linked with how the tumour behaves and progresses. ScienceDirect+2Dove Medical Press+2
Very young age at tumour onset – Children younger than about 2 years at diagnosis often have tumours that grow more quickly and are more likely to need treatment. Again, age is more a risk factor for behaviour than an initial cause. European Review+1
Lack of regular eye screening in NF1 – Not attending regular eye checks does not cause the tumour, but it allows the tumour to grow for longer before being found, which can lead to more severe symptoms when finally diagnosed. Nationwide Children’s Hospital+1
Genetic “hits” during early brain development – Many gliomas likely start when several genetic changes happen in the same cell during early brain growth. These “hits” add up and allow that cell to escape normal controls and become a tumour. Netsolhost+1
Micro-environment around the optic pathway – Supporting cells, blood vessels, and immune cells around the optic nerve can release growth signals or calming signals. In OPG, this local environment may favour growth signals. MDPI+1
Chance (random events) – For some children, no risk factor can be found. In these cases, random genetic mistakes during cell division may be the main reason the tumour appeared. This shows that, sadly, sometimes OPG just happens by chance. Netsolhost+1
Symptoms and signs
Symptoms can be very mild at first and develop slowly. Many children are diagnosed because parents or teachers notice subtle changes in how the child sees or behaves. Nature+1
Blurry vision – The child may say things look fuzzy, may have trouble reading the board at school, or may sit very close to the television or books. This happens because the tumour squeezes the optic nerve and weakens the signal from the eye. Boston Children’s Hospital+1
Reduced visual acuity in one or both eyes – One eye may see worse than the other, or both eyes may be affected. In small children who cannot describe this, parents may notice that the child bumps into objects or favours one eye. Boston Children’s Hospital+2patientinfolibrary.royalmarsden.nhs.uk+2
Visual field loss – Parts of the child’s side vision may be missing. They might not notice things coming from one side, or they may tilt their head to use the part of vision that still works. Netsolhost+1
Squint (strabismus, eye turn) – One eye may turn inward or outward. This can be the first visible sign that something is wrong with the visual pathway, especially if it appears after the baby period. patientinfolibrary.royalmarsden.nhs.uk+1
Nystagmus (flickering eyes) – The child’s eyes may move quickly from side to side or up and down without control. This happens when the brain’s visual pathways are not working properly. PubMed+2Nature+2
Proptosis (eye bulging) – If the tumour grows along the optic nerve behind one eye, that eye can be pushed forward, so it looks more prominent than the other eye. Boston Children’s Hospital+1
Head tilt or odd head posture – Some children keep their head turned or tilted all the time. They may do this to place the clearer part of their visual field into the centre so they can see better. patientinfolibrary.royalmarsden.nhs.uk+1
Colour vision problems – The child may have difficulty telling colours apart, especially red and green, because the optic nerve fibres carrying colour information are affected. Netsolhost+1
Blind spots in vision – Parts of the visual field may disappear, called scotomas. Older children might describe missing letters or parts of images; younger children may just seem clumsy. Netsolhost+1
Headache – If the tumour causes raised pressure inside the skull or blocks normal fluid flow around the brain, the child can have frequent or worsening headaches, especially in the morning. patientinfolibrary.royalmarsden.nhs.uk+1
Nausea and vomiting – Higher pressure in the head can also make a child feel sick or vomit, often along with headaches. These signs can suggest increased intracranial pressure. patientinfolibrary.royalmarsden.nhs.uk+1
Growth and weight changes – Tumours near the hypothalamus can cause poor weight gain with thin appearance (diencephalic syndrome) or, in some cases, rapid weight gain and obesity, depending on which hormone controls are disturbed. ScienceDirect+1
Early or delayed puberty – Damage to the hypothalamus or pituitary gland can cause hormones to start too early (precocious puberty) or too late, leading to changes in height, body hair, and mood at unexpected ages. ScienceDirect+1
Behaviour and learning problems – Some children may become more irritable, tired, or have trouble concentrating at school. This can be due to vision loss, brain pressure, hormone changes, or the stress of illness. Nature+1
Severe visual loss or blindness (late sign) – In a small number of children, especially if the tumour grows for a long time without treatment or is very aggressive, vision can be severely reduced or lost. Boston Children’s Hospital+2Nature+2
Diagnostic tests
Doctors usually use a mix of clinical examination, manual eye tests, laboratory and pathological tests, electrodiagnostic tests, and imaging tests to diagnose and monitor glioma of the paediatric visual pathway. MDPI+2Netsolhost+2
Physical examination tests
1. General paediatric examination – The doctor checks the child’s overall health, height, weight, head size, and vital signs. This helps find signs of long-term illness, poor growth, or raised pressure inside the skull, such as a large head or tense fontanelle in babies. ScienceDirect+1
2. Neurological examination – The doctor tests strength, reflexes, coordination, and balance. Although optic pathway gliomas mainly affect vision, a full neurological exam helps rule out other causes of symptoms and checks for spread or pressure on other brain areas. Netsolhost+1
3. Endocrine and growth examination – Because tumours near the hypothalamus can disturb hormones, the doctor looks for signs of early puberty, delayed puberty, abnormal weight gain or loss, and changes in body hair or growth pattern. ScienceDirect+2European Review+2
Manual eye and bedside tests
4. Visual acuity test (eye chart) – The child is asked to read letters, numbers, or pictures at different distances. In very young children, special cards or toys can be used. This test measures how clearly the child can see with each eye separately. Netsolhost+1
5. Confrontation visual field test – The examiner sits in front of the child and asks them to look at the examiner’s nose while small objects are moved in from the sides. The child says when they see the object. This simple test checks if parts of the side vision are missing. Netsolhost+1
6. Pupillary light reflex test – A small light is shone into each eye to see how the pupils get smaller and larger. In optic pathway glioma, the affected eye may show a weak or delayed response, which signals damage to the optic nerve. Netsolhost+1
7. Extraocular movement test – The doctor asks the child to follow a target (like a pen) in different directions. This checks how the eye muscles move and can show if the tumour is affecting the nerves that control eye movement or causing double vision. Nature+1
8. Funduscopic (ophthalmoscopic) examination – Using a special light and lens, the doctor looks at the back of the eye, including the optic disc (where the optic nerve enters). The disc may look pale (optic atrophy) or swollen, which can help confirm damage from the tumour. Netsolhost+1
Laboratory and pathological tests
9. Basic blood tests – Tests like full blood count, kidney and liver function are not used to diagnose the tumour directly, but they are important to rule out other illnesses and to prepare safely for imaging with contrast or later treatments. MDPI+1
10. Hormone blood tests – Blood tests can measure hormones from the pituitary and hypothalamus, such as growth hormone, thyroid hormones, cortisol, and sex hormones. Abnormal levels show that the tumour may be disturbing the child’s hormone control centres. ScienceDirect+2European Review+2
11. Genetic testing for NF1 – When NF1 is suspected but not clearly diagnosed by skin signs or family history, blood tests can look for changes in the NF1 gene. A positive result confirms NF1, which strongly supports the diagnosis of NF1-associated optic pathway glioma. MDPI+1
12. Tumour biopsy and histopathology – In most children, imaging and clinical features are enough and biopsy is not needed. However, if the tumour looks unusual or behaves aggressively, surgeons may remove a small piece. Under the microscope, pathologists can confirm that it is a low-grade astrocytoma and rule out other tumour types. Netsolhost+1
Electrodiagnostic tests
13. Standard visual evoked potentials (VEP) – In this test, the child looks at a checkerboard or flashing light on a screen while small electrodes on the scalp record the brain’s response. If the optic pathway is damaged, the signals arrive more slowly or are weaker. VEP is sensitive in detecting optic pathway gliomas. PubMed+1
14. Sweep or steady-state VEP – This is a child-friendly version where the pattern changes quickly, and the machine “sweeps” through different sizes or speeds. It can be very helpful for very young children or those who cannot cooperate well with standard tests. IOVS+1
15. Electroretinogram (ERG) – ERG measures electrical activity of the retina itself. In optic pathway glioma, the retina is often normal, so ERG helps doctors confirm that the problem is not in the retina, but further back in the optic nerve or brain. Netsolhost+1
Imaging tests
16. MRI of brain and orbits – Magnetic resonance imaging (MRI) is the main test for optic pathway gliomas. It uses strong magnets, not X-rays, to make detailed pictures of the brain and optic nerves. MRI shows where the tumour is, how big it is, and whether it involves the chiasm or hypothalamus. Ento Key+1
17. Follow-up MRI with contrast – Repeated MRI scans with a contrast dye help doctors watch the tumour over time. They can see if it is stable, shrinking, or growing, and this guides decisions about if or when to start or change treatment. Dove Medical Press+2PMC+2
18. MRI of the spine (when needed) – If doctors are worried that the tumour might spread along the fluid spaces of the brain and spine (leptomeningeal spread), they may order MRI of the spine to look for new tumour deposits. This is uncommon but important to detect early. clinicalradiologyonline.net+1
19. CT scan of brain and orbits – A CT scan uses X-rays to create images and can show enlarged optic nerves or calcification. Today, CT is used less often than MRI for these tumours because MRI shows more detail and avoids radiation, but CT may be used in emergencies or where MRI is not available. Journal of Neurosurgery+1
20. Ocular/orbital ultrasound and PET-CT (special cases) – Ultrasound of the eye socket can help in some cases to show thickening of the optic nerve. PET-CT may be used rarely in research or complex cases to study how active the tumour is. These are not routine tests but can provide extra information when needed. Radiopaedia+1
Non-pharmacological treatments (therapies and other care)
These treatments do not kill the tumour directly. They support the child’s vision, brain function, and quality of life, and they work together with medicines and surgery.
Watchful waiting (active surveillance)
Sometimes the tumour is small and not causing vision problems. In this case, doctors may choose careful monitoring with regular MRI scans and eye tests instead of starting treatment right away. This helps avoid chemotherapy or radiotherapy side effects in very young children. If scans or eye exams show any worsening, treatment is started quickly.MDPI+1Regular ophthalmology (eye) follow-up
Frequent visits to a paediatric ophthalmologist check visual acuity, visual fields and eye movements. Early detection of small changes in vision gives the team time to adjust treatment before serious damage occurs. Eye doctors also help prescribe glasses, low-vision devices, and track how the child’s eyes are coping with treatment.Low-vision rehabilitation
Low-vision therapists teach the child to use remaining sight effectively, with tools like magnifiers, large-print books, high-contrast materials, and special lighting. This makes school work easier and reduces frustration. It also gives parents practical strategies to adapt the home environment so the child can move safely and confidently.Occupational therapy
Occupational therapists help the child with fine motor skills, self-care (dressing, feeding, writing), and school tasks that may be harder due to vision or fatigue. They recommend adaptive tools (special pens, slant boards, larger buttons) and teach routines that keep daily life as independent as possible.Physiotherapy (physical therapy)
Some children develop weakness, balance problems or less physical activity because of the tumour or treatments. Physiotherapists use games and exercises to improve strength, coordination and balance. Regular activity helps the child stay fit, reduces tiredness, and supports healthy bones and muscles.Neuropsychological assessment and cognitive therapy
A paediatric neuropsychologist tests memory, attention, learning and behaviour. They can identify learning difficulties early and design exercises and school strategies to help. This is very important because the tumour and treatments can affect the hypothalamus and other brain areas involved in thinking and emotions.MDPISchool support and special education planning
Many children need extra time, larger print, seating at the front of the classroom, or a teaching assistant. A formal plan (such as an Individualized Education Program where available) makes sure teachers understand the child’s visual limits and fatigue. Good school support protects self-esteem and helps the child keep up with classmates.Psychological counselling and play therapy
Living with a brain tumour is stressful for the child and family. Psychologists and play therapists use age-appropriate games, drawings and stories to help children express fear, anger, or sadness. Parents can also learn coping skills, stress management and ways to communicate honestly but gently with the child.Family and peer support groups
Meeting other families going through similar experiences helps parents feel less alone. Support groups—online or in person—are a place to share practical tips about school, hospital visits and behaviour changes. Children’s groups or camps for kids with cancer can help build friendships and reduce isolation.Nutritional counselling
A paediatric dietitian helps manage weight gain or loss, appetite problems and treatment-related nausea. Good nutrition supports immune function, growth, and energy. The dietitian tailors advice to the child’s culture and preferences, and checks for any vitamin or mineral deficiencies that may require replacement.Sleep hygiene and routine management
Steroid use, anxiety and hospital schedules can disrupt sleep. Simple sleep hygiene steps—fixed bedtimes, quiet and dark bedrooms, avoiding screens late at night—improve rest. Better sleep supports mood, learning and immune function, and may reduce headaches and irritability.Pain and symptom management (non-drug approaches)
Techniques such as relaxation breathing, distraction, music therapy, heat/cold packs and gentle massage can help with mild headaches or muscle pain. These methods work alongside pain medicines and sometimes reduce how much medication is needed.Endocrine and growth monitoring clinics
The visual pathway runs close to the hypothalamus and pituitary gland. Many children develop hormone problems, such as growth hormone deficiency, early or delayed puberty, or thyroid problems. Regular checks by a paediatric endocrinologist help detect and treat these changes early, improving growth, bones and overall health.MDPIRehabilitation for balance and mobility (vision-related orientation)
Orientation and mobility specialists can teach safe ways to move at home, at school and outdoors using visual cues, touch and sometimes canes. This reduces falls and boosts confidence in children with low vision.Social work and financial counselling
Social workers help families handle paperwork, travel, school letters and financial support. They can connect families to charities and resources for equipment or transportation, reducing stress so parents can focus on the child.Palliative and supportive care teams
Palliative care does not only mean “end of life.” It is specialised support at any stage of the disease to control pain, nausea, emotional distress and social problems. This team often includes doctors, nurses, psychologists and spiritual care workers.Radiation-related late-effects clinic (for children who had radiotherapy)
If radiotherapy is needed, long-term follow-up for learning, endocrine and vascular effects is important. Special late-effects clinics monitor these issues and step in early with support, speech therapy or hormone replacements.PMCEye protection and environmental adaptations
Simple steps such as non-slip flooring, clear pathways at home, good lighting and high-contrast colours on stairs and furniture can reduce accidents for a child with limited vision. Sunglasses and hats may reduce light sensitivity outdoors.Exercise and recreation programmes
Safe, age-appropriate physical activity (walking, swimming, non-contact sports) helps maintain heart health, mood and social life. Exercise can also reduce fatigue and anxiety, as long as it is adapted to the child’s energy level and medical restrictions.Spiritual or cultural support (if desired by the family)
Some families find comfort in prayer, religious leaders or traditional practices. When done safely and in coordination with medical teams, these supports can strengthen hope and coping, though they must never replace evidence-based medical treatment.
Drug treatments
Important: Drug choices, doses and timing must always be decided by a paediatric oncology team. Many medicines used for optic pathway glioma in children are off-label, meaning they are not specifically approved by the FDA for this exact tumour, but are supported by studies and guidelines for paediatric low-grade glioma.Journal of Neurosurgery+1
I will focus on key medicines commonly used or studied for paediatric low-grade glioma and brain tumours, mentioning information based on FDA labels (for general indications) and clinical studies.
Carboplatin (platinum chemotherapy)
Carboplatin is an intravenous chemotherapy drug that damages tumour cell DNA so the cells cannot repair themselves and die. It is a core medicine in many standard regimens for paediatric low-grade glioma, usually given every 3–4 weeks, often with vincristine.Journal of Neurosurgery+1 On the FDA label it is approved for ovarian cancer and other solid tumours, with dosing based on body surface area or kidney function. Common side effects include low blood counts, nausea, vomiting and risk of infection.SIOP EuropeVincristine (vinca alkaloid)
Vincristine blocks microtubules, which are tiny tubes needed for cells to divide. It is usually given weekly by intravenous injection in combination with carboplatin for paediatric low-grade glioma.Journal of Neurosurgery+1 It is FDA-approved for several childhood cancers such as acute leukaemia and lymphomas. Side effects include constipation, nerve damage (tingling, weakness), hair loss and low blood counts, so doctors monitor closely.Vinblastine (vinca alkaloid)
Vinblastine is similar to vincristine but often given as single-agent weekly chemotherapy for progressive low-grade glioma. It also interferes with microtubules and cell division.PMC+1 On its label it is approved for Hodgkin’s lymphoma and other cancers. Common side effects are low blood counts, hair loss and fatigue.Temozolomide (TEMODAR – alkylating agent)
Temozolomide is an oral chemotherapy that crosses the blood–brain barrier and adds small chemical groups to DNA, leading to tumour cell death. It is FDA-approved for adult glioblastoma and anaplastic astrocytoma, with dosing in 28-day cycles.FDA Access Data+1 In paediatric low-grade glioma, it is sometimes used off-label, mainly for recurrent disease, but evidence shows it is less effective than carboplatin-based therapy in this group.PMC Side effects include low blood counts, nausea and fatigue.Procarbazine (alkylating agent)
Procarbazine damages tumour cell DNA and is part of older combination regimens such as TPCV (thioguanine, procarbazine, lomustine, vincristine) used in paediatric low-grade glioma.PMC It is given orally in cycles. FDA labelling includes Hodgkin’s disease. Side effects are low blood counts, nausea, vomiting and interactions with certain foods and antidepressants, so diet and drug lists must be checked carefully.Lomustine / CCNU (nitrosourea)
Lomustine crosses the blood–brain barrier and is used in some paediatric low-grade glioma protocols in combination with other drugs (TPCV regimen).PMC It is FDA-approved for primary and metastatic brain tumours in adults and is taken as a capsule every 6 weeks to allow bone marrow recovery. Important side effects include delayed low blood counts and risk of long-term lung and liver toxicity.Etoposide (topoisomerase II inhibitor)
Etoposide interferes with the enzymes that help unwind DNA, leading to breaks in the DNA of dividing cells. Some optic pathway glioma regimens use etoposide with carboplatin or cisplatin for more aggressive disease.MDPI+1 On the FDA label it is approved for lung testicular and other cancers. Side effects include low blood counts, hair loss and nausea.Cisplatin (platinum chemotherapy)
Cisplatin is another platinum drug that crosslinks DNA. It is sometimes used in paediatric glioma regimens, especially when carboplatin is not suitable.MDPI+1 FDA-approved uses include testicular, ovarian and bladder cancers. It can cause kidney damage, hearing loss and nausea, so children receiving cisplatin need strong hydration, anti-nausea medicines and hearing tests.Cyclophosphamide (alkylating agent)
Cyclophosphamide changes DNA in dividing cells, making it harder for tumours to grow. It appears in some intensive regimens for low-grade glioma and other paediatric brain tumours.MDPI+1 It is widely FDA-approved for many cancers and autoimmune diseases. Side effects include low blood counts, hair loss, nausea and bladder irritation, so extra fluids and sometimes protective drugs are used.Bevacizumab (AVASTIN – anti-VEGF monoclonal antibody)
Bevacizumab is a biologic drug that blocks vascular endothelial growth factor (VEGF), a signal that tumours use to grow new blood vessels. The FDA label includes adult glioblastoma (10 mg/kg IV every 2 weeks).FDA Access Data+1 In children with recurrent optic pathway glioma, bevacizumab (often with chemotherapy) has been used off-label to improve vision and shrink tumours in some series. Side effects include high blood pressure, bleeding, protein in the urine and rare serious bowel or clotting problems.MDPISelumetinib (KOSELUGO – MEK inhibitor)
Selumetinib blocks MEK1/2, key proteins in the RAS/RAF/MEK/ERK pathway, which is often over-active in low-grade gliomas, especially those linked to NF1. Phase II studies showed activity in recurrent optic pathway and hypothalamic low-grade gliomas and in children with NF1-related plexiform neurofibromas.PMC+2New England Journal of Medicine+2 The FDA has approved selumetinib for children with NF1 and symptomatic, inoperable plexiform neurofibromas, given as oral capsules or granules twice daily.U.S. Food and Drug Administration+1 Side effects include rash, diarrhoea, heart changes and eye problems, so close monitoring is required.Mirdametinib (Gomekli – MEK inhibitor)
Mirdametinib is another oral MEK inhibitor recently approved by the FDA for adults and children with NF1-associated inoperable plexiform neurofibromas, taken in capsule or dissolvable tablet form.Reuters Although its approval is for NF1-PN, the same signalling pathway is important in many low-grade gliomas, and clinical trials are exploring MEK inhibitors versus carboplatin/vincristine for optic pathway glioma.ClinicalTrials.gov+1 Side effects include rash, diarrhoea, swelling and heart and eye monitoring needs.Trametinib (MEK inhibitor, in trials)
Trametinib is an oral MEK inhibitor approved for certain BRAF-mutated adult cancers. It is being studied in children with low-grade glioma and RAS/RAF pathway changes. It blocks tumour signalling and may shrink or stabilise tumours in some patients. Side effects include rash, diarrhoea, high blood pressure and possible heart or eye toxicity, so it is used only under strict trial or specialist protocols.PMC+1Dabrafenib (BRAF inhibitor, for BRAF-mutant tumours)
Some paediatric low-grade gliomas have BRAF V600E mutations. Dabrafenib targets this abnormal BRAF protein, slowing tumour growth. It is FDA-approved (often with trametinib) for some BRAF-mutated solid tumours, including certain paediatric low-grade gliomas.PMC Side effects can include fever, rash, joint pain and effects on heart and eyes. Genetic testing of the tumour is needed before using this drug.Combination carboplatin/vincristine regimens
Rather than a single drug, many children receive a protocol of carboplatin plus vincristine over 12–18 months. Large international studies have shown this combination can control tumour growth and delay radiotherapy in many children with optic pathway glioma.Journal of Neurosurgery+1 Doses and spacing are carefully planned by paediatric oncologists based on the child’s size and blood counts.Vincristine/cisplatin or etoposide combinations
For more aggressive or recurrent tumours, combinations using vincristine with cisplatin or etoposide have been used. These regimens aim to increase tumour shrinkage but can also increase toxicity, so they are reserved for selected cases or trials.MDPI+1TPCV regimen (thioguanine, procarbazine, lomustine, vincristine)
This is an older multi-drug protocol that has shown long-term control in some paediatric low-grade gliomas. It combines several alkylating drugs and vincristine to attack tumour cells at different points in the cell cycle.PMC Because of cumulative toxicity, this is used with great care.Temozolomide plus carboplatin/vincristine (trial-based)
Some clinical trials have tested adding temozolomide to standard carboplatin/vincristine to see whether this improves control of progressive low-grade glioma.ClinicalTrials.gov These combinations can increase marrow suppression and infection risk, so they are typically restricted to carefully monitored protocols.Steroids (e.g., dexamethasone – short term)
Dexamethasone is not a cancer-killing drug in low-grade glioma but is sometimes used briefly to reduce brain swelling and symptoms such as severe headache or vomiting. However, long-term steroid use is avoided in paediatric low-grade glioma because preclinical evidence suggests it can promote tumour cell survival and cause many side effects (weight gain, mood changes, infections).SIOP Europe+1Supportive medicines (anti-nausea, antibiotics, hormone replacements)
Many other medicines support the child during cancer treatment—anti-emetics to prevent vomiting, antibiotics for infections, hormone replacements (thyroid, cortisol, growth hormone) when the hypothalamus or pituitary are affected. These do not treat the tumour but are essential for safe and effective treatment and healthy development.MDPI+1
Dietary molecular supplements (supportive only, not tumour cures)
Very important: No dietary supplement has been proven to cure or shrink glioma of the paediatric visual pathway. Supplements should only be used if the oncology team agrees, to avoid interactions with chemotherapy.
Vitamin D – Helps bone health and immune function; children on steroids or who move less may have low levels. The doctor may prescribe vitamin D drops or tablets with a dose adjusted to blood tests.
Calcium – Supports strong bones, especially if steroids or reduced activity increase fracture risk. Given in chewable or liquid form, but must be balanced with vitamin D and kidney function.
Omega-3 fatty acids (fish oil or algal oil) – May support heart and brain health and improve appetite in some children. High doses can affect bleeding, so the oncology team must approve.
Probiotics – Sometimes used to support gut health during antibiotics or chemotherapy-related diarrhoea. Only specific, tested products should be used, and not in severely immunocompromised children without oncologist consent.
Multivitamin (child-specific) – A simple paediatric multivitamin can fill small gaps in diet when appetite is poor, but mega-doses are avoided.
Iron supplementation (if anaemia from deficiency) – Only used when blood tests confirm iron deficiency; otherwise it may cause side effects or interact with other medicines.
Folic acid and B-complex – Help red blood cell production and nerve health; used only if there is documented deficiency or poor intake.
Zinc – In small doses, may help immune function and wound healing; high doses can upset copper balance, so it should be monitored.
Vitamin C – Low-dose vitamin C from food or a simple supplement can support general health; very high “alternative” doses are not recommended during chemotherapy without research-based guidance.
Protein supplements (e.g., whey or plant-based powders) – Used to support growth and muscle mass when appetite is poor. A dietitian chooses products and doses so they do not overload the kidneys or replace real food.
Immune-support and regenerative approaches
There are no approved stem-cell drugs or “immunity booster” medicines that cure optic pathway glioma in children. However, doctors sometimes use supportive or experimental approaches:
Granulocyte colony-stimulating factor (G-CSF, e.g., filgrastim/pegfilgrastim)
These biological drugs stimulate the bone marrow to make more white blood cells after chemotherapy, reducing infection risk. They are given as injections for a few days after certain chemo cycles. They do not treat the tumour itself, but they help maintain treatment intensity.Erythropoiesis-stimulating agents (ESA – e.g., erythropoietin) in selected cases
Occasionally used to treat severe anaemia when transfusions are difficult, these drugs signal the bone marrow to produce more red blood cells. They are used carefully because of possible clotting risks and do not affect tumour growth directly.Intravenous immunoglobulin (IVIG) in special circumstances
If chemotherapy or an underlying condition leads to serious antibody deficiency, IVIG may be used to reduce infections. This is a purified antibody product from donors and is given by intravenous infusion.Haematopoietic stem cell transplantation (HSCT)
HSCT is not standard for low-grade optic pathway glioma but may be used for other high-risk brain tumours or blood cancers. It replaces diseased bone marrow with donor stem cells. In the context of optic pathway glioma it is considered experimental and would only occur in specific research or overlapping disease situations.Immune checkpoint inhibitors (e.g., nivolumab, pembrolizumab – trials)
These drugs reactivate T-cells to attack cancer cells. They are FDA-approved for some adult cancers, including certain brain tumours, but their role in paediatric low-grade glioma and optic pathway glioma is still under study. They can cause autoimmune-type side effects and are only used in clinical trials or very selected situations.Regenerative neuro-rehabilitation programmes
While not a drug, intensive rehabilitation that combines physiotherapy, occupational therapy, vision therapy and sometimes neuromodulation aims to help the brain “rewire” and use remaining pathways. This can partly compensate for vision or motor deficits, especially when started early in childhood.
Surgeries (procedures and why they are done)
Stereotactic biopsy
A small piece of the tumour is taken through a tiny opening in the skull using computer-guided tools. This provides tissue for the pathologist to confirm the diagnosis and do molecular tests (such as BRAF or NF1 status). It is done when imaging alone cannot give enough information for treatment planning.Partial tumour debulking
Sometimes a neurosurgeon can safely remove part of the tumour to reduce pressure on nearby structures or improve vision, especially in exophytic tumours that grow outward from the optic pathway. Total removal is often impossible without high risk of blindness or severe hormone problems, so “debulking” aims for symptom relief, not cure.MDPICerebrospinal fluid (CSF) shunt placement
If the tumour blocks normal CSF flow and causes hydrocephalus (fluid build-up in the brain), a shunt can be placed to drain fluid from the brain to the tummy. This reduces headaches, vomiting and risk of brain damage from high pressure.Ommaya reservoir placement
An Ommaya reservoir is a small dome placed under the scalp with a catheter into a ventricle or cyst. It allows doctors to give drugs directly into the CSF or to drain cyst fluid without repeated surgeries. This can help manage cystic components of some gliomas.Optic nerve decompression or eye-related surgery (rare)
In exceptional cases where tumour-related pressure on the optic nerve within the orbit is causing severe pain or rapid vision loss, limited decompression surgery may be considered. More often, eye surgeons perform supportive procedures (like squint correction) to improve eye alignment and comfort rather than tumour removal.
Ways to protect health and reduce risk (what we can and cannot prevent)
We cannot fully prevent glioma of the paediatric visual pathway, especially when it is linked to NF1, which is a genetic condition. But we can reduce complications and catch problems early:
Ensure regular NF1 follow-up with brain MRI and eye exams if the child has NF1.
Report any new vision changes, squint, or unusual eye movements quickly.
Keep all chemotherapy and follow-up appointments so doctors can adjust treatment early.
Keep vaccinations up to date (following oncologist advice) to reduce infection risk.
Encourage balanced nutrition, hydration, and physical activity within medical limits.
Avoid unnecessary exposure to head CT scans and radiotherapy when other tests or treatments are possible (doctors already try to do this).
Teach good hand hygiene to lower infection risk during chemotherapy.
Protect the child from head injuries (seat belts, helmets for bikes where allowed).
Support mental health with open conversation and professional help when needed.
Avoid unproven “miracle cures” from the internet; always discuss new therapies or supplements with the oncology team first.
When to see doctors
You should seek medical help urgently (emergency department) if a child with optic pathway glioma or under treatment has:
Sudden or severe headache, repeated vomiting, or extreme sleepiness.
New or rapidly worsening vision problems (blurred vision, trouble seeing to the side, double vision).
Seizures, sudden weakness, trouble walking, or slurred speech.
High fever, chills, difficulty breathing, or signs of serious infection (especially during chemotherapy).
You should contact the oncology or neurology clinic soon (within days) if you notice:
Gradual change in school performance, attention or behaviour.
Increased thirst or urination, sudden weight gain or loss, or changes in growth or puberty signs.
Ongoing pain not controlled by simple measures.
Any new medicine or supplement you are thinking about giving, so the team can check safety.
What to eat and what to avoid
What to eat (with dietitian and oncology guidance):
Balanced meals with whole grains, lean protein (fish, eggs, beans, chicken), healthy fats and plenty of fruits and vegetables.
Foods rich in protein (lentils, yoghurt, cheese, meats) to support growth and tissue repair.
High-fibre foods such as fruits, vegetables and whole grains to help prevent constipation from medicines like vincristine.
Iron-rich foods (meat, beans, leafy greens) if anaemia is present and approved by the doctor.
Calcium and vitamin-D sources (dairy, fortified plant milks, small fish with bones) to protect bones, especially if steroids are used.
What to avoid or limit (especially during chemotherapy):
Raw or undercooked meat, eggs and unpasteurised milk products, which can carry germs dangerous to children with low white blood cells.
Very high-dose herbal or “immune booster” products that are not checked by the oncology team.
Sugary drinks and junk food in large amounts, which can cause weight gain and poor nutrition.
Energy drinks or high-caffeine drinks, which can worsen sleep and anxiety.
Grapefruit or other foods that strongly affect liver enzymes, unless the oncology team says they are safe with the chosen medicines.
A paediatric oncology dietitian is the best person to design a meal plan that respects local culture, family budget and the child’s taste, while fitting medical needs.
Frequently asked questions (FAQs)
1. Is glioma of the paediatric visual pathway cancer?
It is a type of brain tumour and therefore a cancer, but most cases are low-grade, meaning they grow slowly and often can be controlled for many years. The main concern is protecting vision and healthy development rather than spread to distant organs.MDPI+1
2. Will my child go blind?
Not all children lose vision. Some keep good sight for many years, especially with early detection, careful MRI and eye follow-up, and timely chemotherapy or targeted therapy. However, some children do lose part or all of their vision even with the best treatment.
3. Does every child need surgery?
No. Because the tumour is in a very delicate place, surgery is often limited to biopsy, shunt placement or partial debulking. Many children are treated mainly with chemotherapy and targeted therapy.MDPI+1
4. Is radiotherapy always used?
Radiotherapy can control tumour growth, but it can also cause long-term effects on thinking, hormones and blood vessels, especially in very young children. Modern guidelines try to delay or avoid radiotherapy by using chemotherapy and newer targeted drugs first.PMC+1
5. How long does chemotherapy last?
Standard chemotherapy courses for paediatric low-grade glioma often last 12–18 months or more, with cycles every few weeks. The exact length depends on the protocol, response and side effects.
6. What is a MEK inhibitor and why is it important?
MEK inhibitors (like selumetinib and mirdametinib) block a signalling pathway (RAS/RAF/MEK/ERK) that is often over-active in low-grade glioma and NF1-related tumours. Clinical trials show they can shrink or stabilise tumours in many children and may become part of standard care.PMC+2New England Journal of Medicine+2
7. Are these targeted drugs safer than chemotherapy?
They have different side effects. MEK inhibitors may cause skin rash, diarrhoea, heart and eye changes, while classic chemotherapy often causes low blood counts and hair loss. Neither option is “side-effect free,” so doctors choose based on tumour biology, child’s age and previous treatments.MDPI+1
8. Can diet or vitamins cure the tumour?
No. Healthy food and appropriate supplements support the body, but they cannot replace surgery, chemotherapy, targeted therapy or radiotherapy. Any supplement should be discussed with the oncology team to avoid harmful interactions.
9. Will my child be able to go to school?
Most children can continue school with adjustments such as large-print materials, extra time, and rest breaks. Some may need home teaching for periods during intensive treatment. Good communication between the family, medical team and school is essential.
10. Is this tumour hereditary?
Many optic pathway gliomas occur in children with NF1, which is a genetic condition that can run in families. Other cases are sporadic (no clear family history). Genetic counselling can explain the family’s specific risk.MDPI
11. How often will my child need MRI scans?
In the early years after diagnosis, MRIs are usually done every 3–6 months, sometimes more often if there are changes in symptoms or treatment. Over time, if the tumour is stable, the interval may be lengthened.
12. Can the tumour come back after treatment?
Yes. Even low-grade gliomas can regrow or start growing again after periods of stability. This is why long-term follow-up with MRI and eye exams is very important, even if your child looks and feels well.MDPI+1
13. What is the long-term outlook (prognosis)?
Most children with optic pathway glioma are long-term survivors, especially when the tumour is low-grade. However, many live with chronic issues such as visual impairment, hormonal problems or learning difficulties, so ongoing support is important.
14. Are clinical trials important?
Yes. Clinical trials help test new combinations of chemotherapy, MEK inhibitors, BRAF inhibitors and other targeted drugs to improve control and reduce side effects. Participation is voluntary and carefully regulated; families can discuss options with their oncology team.MDPI+1
15. What is the most important thing parents can do?
The most important things are: keep close contact with the medical team, bring the child to all appointments, report new symptoms early, support emotional health, and ask questions whenever something is unclear. Parents are key partners in the child’s care.
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: December 31, 2025.
